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Recommendations for monitoring and reporting harm in mindfulness for psychosis 
research.   
Summary  
There is increasing interest in potential harmful effects of mindfulness-based 
interventions (MBIs).  In relation to psychosis, inconsistency and shortcomings in how harm 
is monitored and reported are holding back our understanding. We offer eight 
recommendations to help build a firmer evidence base on potential harm in mindfulness for 
psychosis. 
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One of the most significant recent developments in the field of psychotherapy has 
been the emergence of mindfulness-based interventions (MBIs). In relation to psychosis, 
MBIs were slow to develop in large part because of concern that people with psychosis are 
particularly vulnerable to harmful effects arising from mindfulness practice1.  
Operationalising harm in psychotherapy research 
Harm in psychotherapy research has traditionally been defined as the occurrence, 
following an intervention, of a deterioration in symptoms or functioning, which is sustained, 
likely to have been caused by the intervention and more severe than it would have been 
had the individual not received the intervention2.  This definition highlights two immediate 
complexities in defining harm in psychotherapy. First, a proportion of people with mental 
health conditions will experience a deterioration in symptoms with or without an 
intervention, so it is important to establish a baseline rate of deterioration. Randomised 
controlled trials (RCTs) are particularly useful in this regard, as the inclusion of a control arm 
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provides a valid point of comparison from within the same clinical setting and timeframe. 
Second, a deterioration means more than simply a change in score – to determine the 
clinical significance of a change in symptoms or functioning it is helpful to know the minimal 
clinically important difference (MCID) for any given outcome measure.   
A second approach to operationalising harm that is commonly applied in RCTs is to 
report the occurrence of both serious adverse events (SAEs), defined by the World Health 
Organisation as life-threatening or fatal occurrences, and adverse events (AEs), defined as 
untoward events experienced by study participants. SAEs and AEs may or may not be 
caused by the intervention. In a review of the available research on harm in mindfulness-
based psychotherapies across a range of conditions (but not psychosis), Baer et al report 
that AEs or SAEs occur in 0% to 10.6% of research participants, and are no more common in 
mindfulness-based psychotherapies than in comparison conditions2.   
A third approach to operationalising harm has been to consider indirect, or proxy 
indices of harm, such as study drop-out rate – the argument being that drop-out rates 
would be higher in psychotherapies experienced as unsafe by patients.  
Is mindfulness for psychosis harmful? 
The literature on mindfulness-based therapies for psychosis is growing fast. An 
evidence base comprising more than 20 randomised studies (see Jensen et al for the most 
recent meta-analysis3), alongside numerous uncontrolled studies, evidences a range of 
clinical benefits of mindfulness for psychosis, including reduced negative symptoms and 
levels of depression, and enhanced psychological quality of life3. Whilst these randomised 
studies do not suggest that mindfulness for psychosis is harmful, a closer look at how harm 
is operationalised, monitored and reported in mindfulness for psychosis research reveals 
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some critical shortcomings that make it impossible to provide a data-driven answer to the 
question is mindfulness for psychosis harmful?  We offer below eight recommendations 
(summarised in Table 1) on how harm should be operationalised, monitored and reported, 
to strengthen the evidence base on potential harm in mindfulness for psychosis research.  
Recommendations for reporting of harm 
First, whilst uncontrolled research studies were pivotal to the development of 
mindfulness for psychosis, priority should be given to findings from RCTs when drawing 
generalisable conclusions about harm.  The discipline in RCTs of applying a common set of 
study inclusion and exclusion criteria within a standardised recruitment protocol, combined 
with the inclusion of a control arm and random treatment allocation, provides a valid point 
of comparison from which to understand observed levels of harm in those receiving 
mindfulness for psychosis. Whilst uncontrolled studies will always be useful in flagging 
important potential issues of risk and harm, and in ongoing therapy development, they do 
not provide a solid basis for drawing firm conclusions about harm in mindfulness for 
psychosis.  
Second, there are inconsistencies in reporting of SAEs. All future studies should state 
explicitly the number of SAEs by study arm; if there were none, then this should be stated 
explicitly. Whilst this is already a recommendation in reporting of trials it is not always 
applied in the MBI for psychosis literature. Also, there is some confusion about what 
constitutes a SAE in mindfulness for psychosis research. For example, in one study a 
participant death was not reported as a SAE because it was attributed to natural causes. 
Crucially, a SAE is defined by the untoward event itself and not by degree of imputed causal 
connection with study participation.  Whilst it is informative to include indications of likely 
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degree of connection between a life-threatening or fatal occurrence and study participation, 
it always remains a serious adverse event and should be reported as such.  
Third, there is lack of clarity around reporting of hospital admission. As with other 
SAEs, it is sometimes simply not reported on - does this mean it was robustly monitored and 
did not occur, or was not monitored?  Harm in psychotherapy is such an important issue 
that clarity is essential. Data should minimally include the number of participants in each 
arm who were hospitalised – if there were none in a study arm, then this should be stated 
explicitly. If admissions were not monitored, then this should be stated explicitly as a study 
limitation. Where applicable and possible, data on hospital admissions might be 
supplemented by data on usage of crisis or home treatment teams.  
Further inconsistency can arise in trials of MBIs for psychosis that use 
rehospitalisation rate as an outcome measure. Authors typically report admission rates as 
clinical outcomes but not also as adverse events.  This substantially distorts reported rates 
of adverse events in mindfulness research.  Selecting an adverse event as a study outcome 
does not obviate the need to also report it as an adverse event.  Hospital admissions should 
always be reported as adverse events as is done in non-psychotherapy research.  
Fourth, whilst real-world practical constraints mean it is not possible to monitor all 
potential adverse events, what is practicable is for researchers to follow Jacobsen et al4 in 
stating clearly in their Trial Protocol those adverse events which were deemed particularly 
relevant to the trial, specifying how these were monitored (e.g. review of case notes), and 
giving detailed descriptions of any such untoward events that did occur.   
Fifth, researchers are encouraged to consider using a standardized patient-reported 
side effect questionnaire in trials of MBIs, as is done in trials of medication. None of the 
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trials included in the most recent meta-analysis3 of MBIs for psychosis did so. Side effects 
are distinct from adverse events and will occur in all psychotherapies. Recording subjective 
side effects will broaden understanding of potential harm in MBIs for psychosis.  
Sixth, whilst studies increasingly seek to contextualise benefits of MBIs by reporting 
the number of participants who showed a clinically important improvement on measures of 
psychological functioning, it is rare for studies to report how many participants experienced 
a clinically important deterioration.  None of the randomised trials of a MBI for psychosis 
included in the most recent meta-analysis3 of MBIs for psychosis reported data across all 
study arms on clinically important deterioration on the primary measure of psychological 
functioning – and we have found only one RCT published since then that included data on 
clinically important deterioration on the primary outcome measure across all study arms5  
Whenever possible, clinically important symptom deterioration by study arm should be 
reported in all future studies.   
Seventh, whilst drop-out occurs for many reasons, it can be a useful indirect index of 
harm. CONSORT diagrams show study drop out – the number of participants who did not 
provide post-intervention or follow-up data. However, a participant who ceased attending 
therapy yet still provided post-intervention assessment data would not be recorded as a 
study drop-out.  It would be useful for future studies to report not only study drop-out  
(including, where known, the cause of drop out), but also therapy non-completion rates as 
determined against a pre-set number of sessions (e.g. attending minimally 50% of sessions).  
Finally, it will be important in future studies to ensure meaningful public and patient 
involvement (PPI) in research assessing harm. Studies are encouraged to state explicitly if 
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and how PPI input contributed to specific decision making around how harm was 
operationalised and monitored. 
In conclusion, there is a pressing need to improve monitoring and reporting of harm 
in mindfulness for psychosis research – indeed, in the wider literature on MBIs – in order to 
develop a fuller understanding of both beneficial and harmful effects. 
 
Table 1. Summary of recommendations. 
Criteria Recommendations 
1. Study Design i.Data from randomised controlled trial should be prioritised when 
drawing generalisable conclusions about harm in mindfulness for 
psychosis research. 
2. Serious Adverse 
Events 
i.All life-threatening and fatal occurrences should be reported as 
serious adverse events, regardless of degree of causal connection 
with study participation.   
ii.If there were no SAEs, this should be clearly stated. 




i.Hospital admissions should always be reported as adverse events, 
even when hospitalisation is a study outcome.   
ii. If there were none, this should be clearly stated. 
iii.Could be supplemented with data on usage of crisis services if 
possible. 
iv. If they were not monitored, this should be listed as a study 
limitation. 
4. Adverse Events  i.List which instances of less serious adverse events were monitored 
ii.List how they were monitored (e.g. case note review). 
iii.Provide detailed descriptions of any adverse events that occur. 
5. Side effects i.Include standardised patient-reported measure of side effects 
6. Symptom 
Deterioration  
i.All Instances of clinically meaningful deterioration in symptoms or 
psychological functioning should be reported. 
7. Drop Out i.Report study drop out, and reason for drop out (including direct or 
indirect link to harm), by treatment arm.  
ii.Report separately drop out and non-completion of therapy. 
8. Public & Patient 
Involvement 
i.Ensure meaningful PPI in decision-making about how harm is 
operationalised and monitored. 
 
Author contributions. Both authors contributed equally to all aspects of the manuscript.  All 
authors have approved the final version to be published and agree to be accountable for the 




Declaration of interest: None. 
 
Funding Statement: This research received no specific grant from any funding agency, 





1Chadwick P. Mindfulness for psychosis. Brit J Psychiat 2014; 204: 333-334. 
2Baer R, Crane C, Miller E, Kuyken W. Doing no harm in mindfulness-based programs:  
Conceptual issues and empirical findings. Clin Psychol Rev 2019; 71: 101-114.   
3Jensen JE, Gleeson J, Bendall S, Rice S, Alvarez-Jimenez M.  Acceptance and mindfulness- 
based interventions for persons with psychosis: A systematic review and meta 
analysis.  Schizophr Res 2020; 215: 25-37. 
4Jacobsen, P., Peters, E., & Chadwick, P.  (2020).  Mindfulness-based crisis interventions  
for patients with psychotic symptoms on acute psychiatric wards (amBITION study).  
BMC Psychiatry. DOI: 10.1186/s12888-020-02608-x 
5Ellett L, Tarant E, Kouimtsidis C, Kingston J, Vivarelli L, Mendis A, Chadwick P. Group  
mindfulness-based therapy for persecutory delusions: A pilot randomised controlled 
trial.  Schizophr Res 2020.  
 
 
 
